Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Poster Session II

Abstract 383: Candesartan, in a Dose-Related Manner, Upregulates the Protective Axis of the Renal Renin Angiotensin System and Prevents Progression of Diabetic Nephropathy in db/db Mice.

Glaucia E Callera, Danielle Zimermann, Jose Correa, Alexey Gutsol, Ying He, Alvaro Yogi, Aurelie Nguyen Dinh Cat, Ana Briones, Joe Zimpelmann, Kevin Burns, Rhian Touyz
Hypertension. 2012;60:A383
Glaucia E Callera
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Zimermann
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Correa
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexey Gutsol
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying He
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvaro Yogi
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelie Nguyen Dinh Cat
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Briones
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Zimpelmann
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Burns
Kidney Rsch Cntr, Dept. of Medicine, Ottawa Hosp Rsch Institute, Univ of Ottawa, Ontario, Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhian Touyz
Institute of Cardiovascular & Med Sciences, BHF Glasgow Cardiovascular Rsch Cntr Univ of Glasgow, Glasgow, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
  • Info & Metrics
  • eLetters
Loading

Abstract

The renin-angiotensin system (RAS) plays a pivotal role in the pathophysiology of cardiovascular and kidney disease. Protection against kidney injury has been evidenced by high dose angiotensin II (Ang II) type 1 receptor (AT1R) blockers. In this study we sought to determine whether a high dose of candesartan has renoprotective actions associated with the modulation of RAS component expression in type 2 diabetic db/db mice. Systolic blood pressure (SBP), urinary albumin excretion (albumin/creatinine, ACR), and protein expression/activity of RAS components were assessed in db/db and control non-diabetic db/+ mice infused with the AT1R blocker candesartan (1, 5, 25, 75 mg/kg/day, sc, 4 weeks). Vehicle treated db/db mice exhibited increased albuminuria (38.9 ± 11.9 ACR) compared with db/+ mice (6.77 ± 1.7 ACR) with no differences in SBP between the two groups (110 ± 9 vs 116 ± 4 mmHg). Candesartan (1 mg/kg/day) had no effect on SBP, although albuminuria was decreased in db/db mice (8.8 ± 3.0 ACR). Candesartan 5 mg/kg/day reduced SBP only in db/+ mice (92 ± 8 mmHg). Diabetic mice receiving 5mg/kg/day showed less albuminuria compared with vehicle treated db/db mice (21.4 ± 6 ACR). Candesartan 25mg/kg/day reduced SBP in both db/db and db/+ mice (77 ± 5 and 76 ± 4 mmHg) and decreased albuminuria in db/db mice (14.95 ± 6.4 ACR). Reduction in SBP (80 ± 7 mmHg) with no improvement of albuminuria (55.9 ± 6 mmHg) was observed in diabetic mice receiving 75 mg/kg/day candesartan. Histological findings showed that candesartan at low dose, but not at high dose, prevented tubular damage in db/db mice. Candesartan, 1-25 mg/kg/day, increased renal expression of AT2R in db/db mice. Expression of ACE2 and MAS receptor was increased only by candesartan (1 mg) in db/db mice. ACE activity was reduced in plasma and kidney cortex of db/db mice, without effect of candesartan. ACE2 activity was increased by candesartan in plasma (5 mg/kg/day) and kidney cortex (1 mg/kg/day) from db/db mice. These results indicate that low to intermediate doses of candesartan reduce the magnitude of albuminuria and tubular damage in diabetic nephropathy. These effects were not evidenced at a higher dose of candesartan. Such processes may be due to activation of the protective axis (ACE2/MAS/AT2R) of the renal RAS.

  • Angiotensin II
  • diabetic
  • Kidney
  • © 2012 by American Heart Association, Inc.
Back to top
Previous Article

This Issue

Hypertension
September 2012, Volume 60, Issue Suppl 1
  • Table of Contents
Previous Article

Jump to

  • Article
  • Info & Metrics

Article Tools

  • Citation Tools
    Abstract 383: Candesartan, in a Dose-Related Manner, Upregulates the Protective Axis of the Renal Renin Angiotensin System and Prevents Progression of Diabetic Nephropathy in db/db Mice.
    Glaucia E Callera, Danielle Zimermann, Jose Correa, Alexey Gutsol, Ying He, Alvaro Yogi, Aurelie Nguyen Dinh Cat, Ana Briones, Joe Zimpelmann, Kevin Burns and Rhian Touyz
    Hypertension. 2012;60:A383, originally published October 14, 2015

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Abstract 383: Candesartan, in a Dose-Related Manner, Upregulates the Protective Axis of the Renal Renin Angiotensin System and Prevents Progression of Diabetic Nephropathy in db/db Mice.
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Abstract 383: Candesartan, in a Dose-Related Manner, Upregulates the Protective Axis of the Renal Renin Angiotensin System and Prevents Progression of Diabetic Nephropathy in db/db Mice.
    Glaucia E Callera, Danielle Zimermann, Jose Correa, Alexey Gutsol, Ying He, Alvaro Yogi, Aurelie Nguyen Dinh Cat, Ana Briones, Joe Zimpelmann, Kevin Burns and Rhian Touyz
    Hypertension. 2012;60:A383, originally published October 14, 2015
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured